Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of VAV1 in preparation of medicine for treating central nervous system inflammation

A central nervous system, VAV1 technology, applied in the field of biomedicine, can solve the problems of uncontrolled central inflammatory response, incision is difficult to heal, water and sodium retention, etc., and achieves good biodegradability, prolonged half-life, and good tissue penetration. Effect

Active Publication Date: 2020-09-29
NANTONG UNIVERSITY
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, for aseptic acute inflammation caused by central nervous system injury, hormones such as methylprednisolone and dexamethasone are mainly used for intervention treatment, but in addition to little curative effect, it will also cause water and sodium retention and difficult healing after incision and other adverse reactions
At present, there is no specific target drug to control the central inflammatory response at home and abroad
There is no report on the relationship between VAV1 and other diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VAV1 in preparation of medicine for treating central nervous system inflammation
  • Application of VAV1 in preparation of medicine for treating central nervous system inflammation
  • Application of VAV1 in preparation of medicine for treating central nervous system inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] The preparation of embodiment 1 rat source VAV1 protein

[0042]Get SD rat blood, after Trizol method extracts total cell RNA, utilize reverse transcription kit (Qiagen, Germantown, MD, USA) to prepare cDNA, use Takara company PCR kit to analyze rat source VAV1 sequence (Genbank: BC091160, SEQ ID No: 1) PCR amplification (amplification primer: forward primer 5'-ctc gag gag ctctgg cga cag tg acc-3', SEQ ID No: 2; reverse primer 5'-cat atg gca gta ttc agaata gtc-3 ', SEQ ID No: 3. Amplification conditions: 1μl cDNA template, 19μl PCR reaction buffer containing 2.5mmol / L MgCl2, 0.2mmol / L dNTPs, forward and reverse primers 0.5μmol / L, DNA polymerase 0.2μl and 1× DNA polymerase buffer; reaction conditions: 94°C for 5min; 94°C for 30sec, 38 cycles; 60°C for 30sec; 72°C for 30sec); prepare 1% agarose gel (0.5g agarose powder, 50ml 1×TAE After repeated boiling in a microwave oven for 3 times, add 5 μl of Gel Red at a ratio of 1:10,000 after the temperature of the solution has d...

Embodiment 2

[0045] The preparation of the chitosan nano-microsphere system of embodiment 2 direct method loading rat source VAV1 protein

[0046] VAV1 protein (1 mg / mL) and chitosan (3 mg / mL) with a molecular weight of 5000 were dissolved in an aqueous solution, and the aqueous solution of VAV1 protein was added dropwise to the aqueous solution of chitosan under stirring conditions to form a load. Chitosan nanosphere system of VAV1 protein. Stirring and reacting for 60 minutes, a slow-release system loaded with VAV1 protein was obtained, the loading efficiency of the protein was 91%, and the average particle diameter of the nanospheres was 130nm.

Embodiment 3

[0047] Example 3 Preparation of cross-linked chitosan nanosphere system loaded with rat source VAV1 protein by poor solvent-cross-linking method

[0048] 1 mL of chitosan (3 mg / mL) with a molecular weight of 5000 was dissolved in an aqueous solution, and under stirring conditions, 1.5 mL of ethanol was added to form a poor solvent to prepare chitosan nanospheres. Add 100 mg polyethylene glycol acrylate (molecular weight: 1000) to cross-link the nanospheres. After centrifugation, redisperse and add 0.1 mL of VAV1 protein (1 mg / mL) to obtain a chitosan nanosphere system loaded with VAV1 protein. SEM image of chitosan nanospheres loaded with VAV1 protein image 3 shown. The average particle size of the nano-microspheres is 120nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of VAV1 in preparation of a medicine for preventing and / or treating central nervous system inflammation or central nervous system diseases related to the inflammation. According to application in the invention, found from comparative studies of a spinal cord injury non-inflammatory animal model and a spinal cord injury induced inflammatory animal model, the VAV1protein has the effect of inhibiting inflammatory response of inflammatory cells and glial cells in central nervous tissues, provides new research ideas for developing medicines for treating centralnervous inflammation, and provides a new therapeutic method for treatment and functional rehabilitation of iatrogenic brain injury, cerebral trauma and spinal cord injury.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of VAV1 in the preparation of drugs for preventing and / or treating central nervous system inflammation or inflammation-related central nervous system diseases. Background technique [0002] Inflammation of the central nervous system is a complex innate immune response in the pathological state of the central nervous system or after injury. Under normal circumstances, microglia (MG) and astrocytes (AC) in the central nervous system are in a quiescent state, maintaining the normal tissue homeostasis of the central nervous system. When the brain or spinal cord is infected or injured, activated microglia, reactive astrocytes, invading T cells, and excessively produced inflammatory mediators together constitute a neuroinflammatory response that endangers the survival of neurons. Many studies have shown that in the process of neurodegeneration, inflammation can in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K38/17A61K9/14A61K47/69A61P25/00A61P29/00A61P25/28A61P25/14A61P31/04
CPCA61K45/00A61K38/1709A61K9/0024A61K9/146A61P25/00A61P29/00A61P25/28A61P25/14A61P31/04
Inventor 王勇军张鲁中王莹洁杜楠宋红花何兵强
Owner NANTONG UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com